Childhood head and neck cancer in France: Incidence, survival and trends from 2000 to 2015.

Childhood head and neck cancers (HNC) are rare and represent a complex group of anatomical topographies. The aim of this study is to describe the distribution, the incidence and survival rates of children with malignant HNC in France. A population-based study was conducted between 2000 and 2015 in children less than 15 years with a diagnosis of HNC using the French National Registry of Childhood Cancers database (RNCE). Age-standardized incidence rates (ASR) and survival analysis were performed. The 1623 included HNC represented 5.6% of all cancers included in the RNCE. The thyroid was the leading tumor site category (26.6%), followed by head and neck soft tissue location (15.4%) and the nasopharynx (10.8%). The most common cancers were thyroid gland carcinomas (26.1%), rhabdomyosarcomas (23.9%) and Burkitt Lymphomas (8.6%). Nasopharynx cancers and soft-tissue sarcomas were statistically more frequent in boys, while thyroid carcinomas were significantly more frequent in girls. The annual ASR was 8.6 new cancer cases per million children. For all HNC combined, the 5-year overall survival (OS) was 87.7% [95%CI: 85.9–89.2]. There was no statistically significant variation in 5-year OS between 2000-2007 and 2008–2015. Epidemiological data on HNC distribution, incidence and survival contributes to better understand these tumors by quantifying their impact on the French population and assessing their burden. Regarding the exclusion of topographies and some histological origins performed by some authors, this report proposes new recommendations to study HNC in a pediatric population. • Main sites: thyroid (27%), pharynx (17%), and head and neck soft tissue (15%) • Histologies: carcinomas (37%), rhabdomyosarcomas (24%), Burkitt lymphomas (9%) • Annual age-standardized incidence rate, 8.6 per million children, stable over time • 5-year overall survival: 88%, lowest for rhabdoid tumors (29%), osteosarcomas (65%) • Better 5-year OS for H&N compared to all sites for neuroblastomas and Ewing tumors [ABSTRACT FROM AUTHOR]